Trial Profile
A pharmacokinetic interaction between the HCV Protease Inhibitor grazoprevir and intravenous and oral rifampicin in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Dec 2015
Price :
$35
*
At a glance
- Drugs Grazoprevir (Primary) ; Rifampicin
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 12 Dec 2015 New trial record